256 related articles for article (PubMed ID: 15472806)
1. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.
Krause DS; Simjee AE; van Rensburg C; Viljoen J; Walsh TJ; Goldstein BP; Wible M; Henkel T
Clin Infect Dis; 2004 Sep; 39(6):770-5. PubMed ID: 15472806
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
[TBL] [Abstract][Full Text] [Related]
3. Anidulafungin versus fluconazole for invasive candidiasis.
Reboli AC; Rotstein C; Pappas PG; Chapman SW; Kett DH; Kumar D; Betts R; Wible M; Goldstein BP; Schranz J; Krause DS; Walsh TJ;
N Engl J Med; 2007 Jun; 356(24):2472-82. PubMed ID: 17568028
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.
de Wet NT; Bester AJ; Viljoen JJ; Filho F; Suleiman JM; Ticona E; Llanos EA; Fisco C; Lau W; Buell D
Aliment Pharmacol Ther; 2005 Apr; 21(7):899-907. PubMed ID: 15801925
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.
Ally R; Schürmann D; Kreisel W; Carosi G; Aguirrebengoa K; Dupont B; Hodges M; Troke P; Romero AJ;
Clin Infect Dis; 2001 Nov; 33(9):1447-54. PubMed ID: 11577374
[TBL] [Abstract][Full Text] [Related]
6. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Petraitis V; Petraitiene R; Groll AH; Sein T; Schaufele RL; Lyman CA; Francesconi A; Bacher J; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):471-9. PubMed ID: 11158743
[TBL] [Abstract][Full Text] [Related]
7. Anidulafungin: a new echinocandin with a novel profile.
Vazquez JA
Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
[TBL] [Abstract][Full Text] [Related]
8. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.
Viljoen J; Azie N; Schmitt-Hoffmann AH; Ghannoum M
Antimicrob Agents Chemother; 2015 Mar; 59(3):1671-9. PubMed ID: 25561337
[TBL] [Abstract][Full Text] [Related]
9. Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
Hamza OJ; Matee MI; Brüggemann RJ; Moshi MJ; Simon EN; Mugusi F; Mikx FH; van der Lee HA; Verweij PE; van der Ven AJ
Clin Infect Dis; 2008 Nov; 47(10):1270-6. PubMed ID: 18840077
[TBL] [Abstract][Full Text] [Related]
10. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Keating G; Figgitt D
Drugs; 2003; 63(20):2235-63. PubMed ID: 14498760
[TBL] [Abstract][Full Text] [Related]
11. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study.
Barbaro G; Barbarini G; Di Lorenzo G
Scand J Infect Dis; 1995; 27(6):613-7. PubMed ID: 8685642
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole vs. flucytosine in the treatment of esophageal candidiasis in AIDS patients: a double-blind, placebo-controlled study.
Barbaro G; Barbarini G; Di Lorenzo G
Endoscopy; 1995 Jun; 27(5):377-83. PubMed ID: 7588352
[TBL] [Abstract][Full Text] [Related]
13. Anidulafungin.
Murdoch D; Plosker GL
Drugs; 2004; 64(19):2249-58; discussion 2259-60. PubMed ID: 15456342
[TBL] [Abstract][Full Text] [Related]
14. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.
Vazquez JA; Skiest DJ; Nieto L; Northland R; Sanne I; Gogate J; Greaves W; Isaacs R
Clin Infect Dis; 2006 Apr; 42(8):1179-86. PubMed ID: 16575739
[TBL] [Abstract][Full Text] [Related]
15. Anidulafungin and fluconazole for candidiasis.
Nir-Paz R; Moses AE
N Engl J Med; 2007 Sep; 357(13):1347-8; author reply 1348. PubMed ID: 17902202
[No Abstract] [Full Text] [Related]
16. Anidulafungin in the treatment of patients with invasive candidiasis.
Kett DH; Cubillos GF
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole.
Kartsonis N; DiNubile MJ; Bartizal K; Hicks PS; Ryan D; Sable CA
J Acquir Immune Defic Syndr; 2002 Oct; 31(2):183-7. PubMed ID: 12394797
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology and antifungal properties of anidulafungin, a new echinocandin.
Estes KE; Penzak SR; Calis KA; Walsh TJ
Pharmacotherapy; 2009 Jan; 29(1):17-30. PubMed ID: 19113794
[TBL] [Abstract][Full Text] [Related]
19. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.
Villanueva A; Gotuzzo E; Arathoon EG; Noriega LM; Kartsonis NA; Lupinacci RJ; Smietana JM; DiNubile MJ; Sable CA
Am J Med; 2002 Sep; 113(4):294-9. PubMed ID: 12361815
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.
Neoh CF; Liew D; Slavin M; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
J Antimicrob Chemother; 2011 Aug; 66(8):1906-15. PubMed ID: 21628305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
